Corpus Intelligence IC Memo — CALVARY HOSPITAL INC. 2026-04-26 17:53 UTC
IC Memo — CALVARY HOSPITAL INC.
Investment Committee Memorandum | NY | 225 beds | Grade C | EBITDA uplift $8.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CALVARY HOSPITAL INC.

CCN 332006 | BRONX, NY | 225 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CALVARY HOSPITAL INC. is a 225-bed suburban community hospital in BRONX, NY with $120.4M in net patient revenue and a -16.7% operating margin. The hospital serves a payer mix of 59.2% Medicare, 8.9% Medicaid, and 31.9% commercial.

Thesis: Undervalued. Our ML models identify $8.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -16.7% to -9.3% (+736bps).

Net Revenue HCRIS$120.4M
Current EBITDA COMPUTED$-20.1M
Operating Margin COMPUTED-16.7%
Occupancy HCRIS95.6%
Revenue / Bed COMPUTED$535K
Net-to-Gross HCRIS53.9%
Distress Probability ML44.2%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
96
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -16.7% places it above the state median. Among 96 size-comparable peers (112-450 beds), the median margin is -17.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (112-450), prioritizing same-state peers. 96 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CALVARY HOSPITAL INC. (Target)NY225$120.4M-16.7%
LENOX HILL HOSPITALNY415$1.32B-35.1%
JACOBI MEDICAL CENTERNY440$1.14B-16.8%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
NYC HEALTH+HOSPITAL/KINGS COUNNY381$1.03B-15.0%
ST. FRANCIS HOSPITALNY364$889.3M2.0%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ELMHURST HOSPITAL CENTERNY358$862.7M-9.5%
MOUNT SINAI HEALTH SYSTEM-BETHNY437$801.8M-33.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.5M+210bp18mo
Cost to Collect4.5%2.5%$2.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.5M+122bp9mo
Clean Claim Rate88.0%96.0%$77K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.5M
Cost to Collect
$2.4M
Denial Rate Reduction
$2.4M
A/R Days Reduction
$1.5M
Clean Claim Rate
$77K
Total EBITDA Uplift$8.9M
Current EBITDA$-20.1M
+ RCM Uplift+$8.9M
Pro Forma EBITDA$-11.2M
Current Margin-16.7%
Pro Forma Margin-9.3%
WC Released (1x)$4.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-30.9M$-43.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-30.9M$-58.3M0.00x-100.0%
Bull Case9.0x11.0x$-27.8M$-39.1M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-27.8M$-50.8M0.00x-100.0%
Bear Case11.0x10.0x$-34.0M$-78.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-34.0M$-97.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumHeavy Medicare dependenceMedicare comprises 59.2% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 96 hospitals with 112-450 beds
  • Same-state prioritization (n=97)
  • Comp margins: P25=-27.9% / P50=-17.6% / P75=-9.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.